Payment overview · 2025
General Payments
$281.29
16 reported records · 11 companies
Healthcare provider profile · identity verified
S Karen Evans, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBUQUERQUE, NM · NPI 1144251778
Verified facts
What the public records show
CMS Open Payments records show S Karen Evans, MD received $281.29 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.70 | 21.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.71 | 12.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.93 | 11.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.62 | 9.8% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.02 | 7.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.17 | 7.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.72 | 7.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.98 | 6.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.65 | 5.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.30 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.49 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.29 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.70 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.62 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 774 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 716 | 210 |
| Gabapentin | Gabapentin | 516 | 93 |
| Losartan Potassium | Losartan Potassium | 504 | 153 |
| Lisinopril | Lisinopril | 470 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 125 |
| Omeprazole | Omeprazole | 250 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 78 |
| Simvastatin | Simvastatin | 227 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 67 |
| Trazodone Hcl | Trazodone Hcl | 207 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 59 |
| Sertraline Hcl | Sertraline Hcl | 162 | 41 |
| Metformin Hcl Er | Metformin Hcl | 161 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 42 |
| Mirtazapine | Mirtazapine | 139 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 50 |
| Alendronate Sodium | Alendronate Sodium | 131 | 48 |
| Baclofen | Baclofen | 122 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 35 |
| Meloxicam | Meloxicam | 113 | 31 |
| Tramadol Hcl | Tramadol Hcl | 108 | 30 |
| Bupropion Xl | Bupropion Hcl | 106 | 26 |
| Famotidine | Famotidine | 99 | 28 |
| Estradiol | Estradiol | 96 | 36 |
| Metformin Hcl | Metformin Hcl | 95 | 26 |
| Furosemide | Furosemide | 93 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 21 |
| Lovastatin | Lovastatin | 84 | 23 |
| Pregabalin | Pregabalin | 82 | 16 |
| Eliquis | Apixaban | 79 | 25 |
| Ozempic | Semaglutide | 79 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 33 |
| Xarelto | Rivaroxaban | 75 | 21 |
| Allopurinol | Allopurinol | 73 | 20 |
| Potassium Chloride | Potassium Chloride | 72 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 69 | 21 |
| Celecoxib | Celecoxib | 67 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Myrbetriq | Mirabegron | 65 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | suppressed |
| Spironolactone | Spironolactone | 59 | 11 |
| Carvedilol | Carvedilol | 56 | 16 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Acyclovir | Acyclovir | 51 | 21 |
| Cephalexin | Cephalexin | 51 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 15 |
| Alprazolam | Alprazolam | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 24 |
| Lorazepam | Lorazepam | 39 | 18 |
| Farxiga | Dapagliflozin Propanediol | 37 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 15 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Prednisone | Prednisone | 35 | 24 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Felodipine Er | Felodipine | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Naproxen | Naproxen | 20 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.29 · 16 records | Amgen Inc. | CRYSVITA, EVENITY, FARXIGA, JARDIANCE, MOUNJARO, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, YUPELRI, ZENPEP, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error